去势抵抗性前列腺癌的药物治疗现状

Current status of drug therapy for castration-resistant prostate cancer

雄激素剥夺疗法(ADT)一直是晚期前列腺癌的代表性疗法。当前列腺癌进展为去势抵抗性前列腺癌(CRPC)时,ADT的抗性也随之出现。目前,多西他赛是首个被美国食品药品监督管理局(FDA)批准用于CRPC的细胞毒性化疗药物。另外,还有阿比特龙、恩杂鲁胺等药物也获得FDA批准,且这些药物都显示出良好的生存获益。本文对这些疗法的临床试验和生存获益进行了回顾,并对这一领域的新兴药物进行了讨论。本综述将对CRPC的药物治疗现状进行陈述,并为临床用药提供参考。

Androgen deprivation therapy(ADT)has always been a representative therapy for advanced prostate cancer.When prostate cancer progresses to castration resistant prostate cancer(CRPC),ADT resistance also emerges.Currently,docetaxel is the first cytotoxic chemotherapy drug approved for CRPC.In addition,abiraterone,enzalutamide and other drugs have also been approved by FDA,and these drugs have shown good survival benefits.In this article,we reviewed the clinical trials and survival benefits of these therapies,and discussed emerging drugs in this field.This review will describe the current status of CRPC drug treatment and provide references for clinical medication.